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Abstract
Background Lymphocytic colitis (LC) can be mistakenly
diagnosed as irritable bowel syndrome (IBS). In a previous
study on IBS, some patients showed extremely high colo-
nic chromogranin A cell density. Further examination of
these patients showed that they suffered from LC.
Aims To investigate whether chromogranin A cell density
is increased in LC patients and to examine the possibility of
using this increase as a marker for the diagnosis of LC.
Methods Fifty-seven patients diagnosed with LC and 54
controls were included in the study. Biopsies from the right and
left colon were obtained from both patients and controls, which
were immunostained using the Avidin–biotin-complex method
for chromogranin A, and cell density was quantified.
Results In both the right and left colon of patients with LC,
the density of chromogranin A was significantly higher than in
controls. This increase in chromogranin A cells occurs whe-
ther the number of these cells is expressed as number/mm2
epithelium or as number/field. Chromogranin A cell density
for the right and left colon expressed as number of cells/mm2
epithelium or as cell number/field showed a high sensitivity
and specificity as a diagnostic marker for LC.
Conclusions Chromogranin A is a common marker for
endocrine cells, and the present finding suggests that
colonic hormones are involved in the pathophysiology of
LC. The chromogranin cell density seems to be a good
diagnostic marker with high sensitivity and specificity in
both the right and left colon, thus sigmoidoscopy can be
used in the diagnosis of LC using with this marker.
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Introduction
Microscopic colitis (MC) is a chronic condition, which is
characterized by watery diarrhea with normal radiologic
and endoscopic findings. However, histopathological
examinations of the colon reveal abnormal histology [1],
which is of two distinctive types: lymphocytic colitis (LC)
and collagenous colitis (CC) [1]. LC exhibits an increased
number of colonic intra-epithelial lymphocytes ([20/100
epithelial cells), increased inflammatory cells within lam-
ina propria, and preserved crypt architecture [1]. Popula-
tion-based studies in Europe and in the United States have
reported an incidence of LC ranging from 3.1 to 9.8 per
100,000 [2–10]. The prevalence of LC in Europe and the
United States in population-based investigation has been
found to be 14.2 per 100,000 population [2–9].
LC and irritable bowel syndrome (IBS) have similar
symptoms and a normal endoscopic appearance, as well as
normal radiologic findings [10, 11]. Several studies have
shown that LC can be mistakenly diagnosed as IBS [12, 13].
In a study on the colonic chromogranin A cell density in IBS
patients [13], nine patients out of 50 showed extremely high
colonic chromogranin A cell density [13]. This high density
was in contrast to the low density of chromogranin cells in
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the rest of the IBS patients studied [13]. Further examination
of these nine patients showed that they suffered from LC,
although they fulfilled the Rome III criteria for IBS [13].
The symptoms of LC suggest an abnormally rapid
intestinal motility and a decrease in the absorption of water.
The neuroendocrine system of the gut plays a significant role
in regulating gut motility, as well as the absorption of water
and salts [14–17]. It is reasonable to assume, therefore, that
colonic endocrine cells may be affected, and may be
involved in the pathophysiology of this disorder. Chro-
mogranin A is a 68-kDa protein comprising 439 amino acid
residues, which was isolated for the first time from secretory
granules of the bovine adrenal medulla [18]. Chromogranin
A is co-stored and co-released with monoamines and peptide
hormones of the adrenal medulla, pituitary gland, parathy-
roid, thyroid C-cells, pancreatic islets, endocrine cells of the
gastrointestinal tract, and sympathetic nerves [19–20].
Therefore, chromogranin A is considered to be a general
marker for all endocrine cells.
The current study was undertaken to examine the colonic
chromogranin cell density in a patient cohort with LC in
order to establish whether a higher density of these cells
occur, and to further examine the possibility of using colonic
chromogranin A as a marker for the diagnosis of LC.
Materials and Methods
Patients and Controls
Fifty-seven patients diagnosed with LC during the period
from 2007 to 2010 in all three hospitals of the Helse-Fonna
region in western Norway, namely, Stord, Haugesund, and
Odda hospitals, were included in this study. These patients
included 41 females and 16 males, with an average age of
49 years (range 19–84 years). Fifty-four subjects that
underwent colonoscopy with biopsies were used as controls.
These subjects underwent colonoscopy because of gastro-
intestinal bleeding, where the source of bleeding was iden-
tified as hemorrhoids (26) and angiodysplasia (8), and a
further 20 subjects were tested because of health worries
caused by a relative being diagnosed with colon carcinoma.
The control group was comprised of 38 females and 16
males, with an average age of 49 years (range 18–67 years).
The study was performed in accordance with the
Declaration of Helsinki and was approved by the local
Committee for Medical Research Ethics. All subjects gave
oral and written consent.
Colonoscopy
Colonoscopy was performed in patients and controls and
two biopsies were taken from the cecum, from both the
ascending colon and the right half of the transverse colon.
All biopsies were pooled together and used as right colon,
regardless of gender. In addition, two biopsies were taken
from the left half of transverse colon, from the descending
colon, and from the sigmoid colon. These six biopsies were
pooled together and used as left colon.
Histopathology and Immunohistochemistry
Biopsies were fixed in 4 % buffered paraformaldehyde
overnight, embedded in paraffin and cut into 5-lm-thick
sections. The sections were stained by hematoxylin and
eosin (H&E) and immunostained with the avidin–biotin-
complex (ABC) method using the Vectastain ABC-kit
(Vector Laboratories) as described previously [21]. The
primary antibody used was a monoclonal mouse anti-N-
terminal of purified chromogranin A (DakoCytomation,
code no. M869). The antibody was used at dilutions of
1:1,500. The second layer, biotinylated mouse anti-IgG
was obtained from DakoCytomation. Negative and positive
controls were the same as those described previously [21].
Computerized Image Analysis
The number of chromogranin A immunoreactive cells and the
area of the epithelial cells was measured using Olympus
software: Cell ^D. When using 409 objectives, the frame
(field) on the monitor represented an area of 0.14 mm2 of the
tissue. Measurements were performed in ten randomly chosen
fields for each individual. The immunostained sections of
patients and controls were coded and mixed, and measure-
ments were made without the knowledge of sections identity.
The 409 objective was used. The data from fields were tab-
ulated, the number of cells/mm2 of epithelium was computed,
and statistical analysis was performed automatically. The
number of chromogranin A immunoreactive cells was also
counted per microscopic field in 10 fields for each individual.
Statistical Analysis
As the results of controls and patients passed the normality
test, the t test was performed. p \ 0.05 was considered to
be statistically significant.
Results
Endoscopy, Histopathology,
and Immunohistochemistry
The colons of patients and control subjects were shown to
be macroscopically normal. Histopathological examination
of the colon biopsies from controls revealed normal
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histology and those from patients showed typical LC
histopathology.
Computerized Image Analysis
The chromogranin A cell density in the right colon of the
controls was 21.5 ± 0.5 per mm2 epithelium (mean ± SE),
and in the left colon was 27.2 ± 1.4 per mm2 epithelium.
Chromogranin A cell density was significantly higher in
the right colon than in the left (p = 0.02). The number of
chromogranin A cells per field in the right colon of controls
was 9.3 ± 0.5 and in the left colon was 8.9 ± 0.6. There
was no significant difference between right and left colon
regarding the number of chromogranin A cells per field
(p = 0.3). The chromogranin A cell density in the right
colon of patients with LC was 68.8 ± 4 per mm2 epithe-
lium, and in the left colon was 87 ± 4 per mm2 epithe-
lium. The cell density of chromogranin A was higher in the
left colon than in the right colon of patients with LC
(p = 0.002). In patients with LC, the number of chro-
mogranin A cells per field in the right colon was 38.7 ± 2
and in the left colon was 36.6 ± 2. There was no signifi-
cant difference in the number of chromogranin A cells per
field between right and left colon in patients with LC.
In both the right and left colon of patients with LC, the
density of chromogranin A was significantly higher than in
controls (Fig. 1). The increase in chromogranin A cells in
patients with LC occurred whether the number of these
cells was expressed as number/mm2 epithelium or as
number/field (Figs. 2, 3).
Receiver-operator characteristic (ROC) curves for chro-
mogranin A cell density for the right and left colon show that
in the right colon at a cut-off value of [30 cells/mm2 epi-
thelium, the sensitivity is 97 % and specificity is 98 %. In the
left colon, at a cut-off of [29 cells/mm2 epithelium the
sensitivity is 100 % and specificity is 94 % (Fig. 4).
ROC curves for chromogranin A cell number/field for
the right colon shows that at a cut-off of[15 cells/field, the
Fig. 1 Chromogranin A-immunoreactive cells in the colon of a
control (a) and a patient with lymphocytic colitis (b)
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Fig. 2 Chromogranin A cell density in the controls and patients with
lymphocytic colitis as expressed per mm2 epithelium: in the right
colon (a) and left colon (b). **p \ 0.01, ***p \ 0.001
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sensitivity is 98 % and specificity is 96 %. In the left colon,
at cut-off values of [15 cells/field, the sensitivity is 93 %
and specificity is 89 % (Fig. 5).
Discussion
The chromogranin A cell density was significantly higher
in the right colon than in the left colon when the number of
cells was counted with regards to epithelium cell numbers,
but not when it was analyzed by microscopic field. In
patients with LC, it was the opposite, where the left colon
had a higher density of chromogranin cells. Again, there
was no difference in chromogranin cell density between the
right and left colon when the cells were analyzed per
microscopic field. However, the significant difference
obtained here could be a statistical type I error. The dif-
ference between the outcome when the number of chro-
mogranin cells was compared to epithelium or microscopic
field could be due the fact that chromogranin cells, which
are situated among the epithelial cells, are more counted
with regards to epithelium.
As chromogranin A is a common marker for endocrine
cells, the current finding of a high density of colonic
chromogranin A cells in patients with LC suggests that
colonic hormones are involved in the pathophysiology of
LC. Several studies present solid evidence for the inter-
action of the gut neuroendocrine peptides/amines and the
local immune system in the gut. This is referred to as the
endocrine/immune axis [22]. Thus, chromogranin-derived
peptides, such as chromofugin and vasostatin-I, are able to
penetrate into polymorphonuclear neutrophils, inducing an
extracellular calcium entry [23]. This study illustrates the
role of chromogranins in active communication between
the neuroendocrine and immune system. Moreover, the
chromogranin-derived peptide, catestatin stimulates che-
motaxis of human peripheral blood monocytes [24, 25].
Secreoneurin, a chromogranin-derived peptide, reduces
IL-6 release from eosinophils [26]. In addition, chro-
mogranin-derived peptides modulate the endothelial per-
meability during inflammatory processes. Chromogranin A
prevents the vascular leakage induced by the tumor
necrosis factor (TNF)-alpha in a mouse model [26]. It is
noteworthy that colonic chromogranin A cells have been
b
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Fig. 3 Chromogranin A cell density expressed as he number of cells per field in controls and patients with lymphocytic colitis: in the right colon
(a) and left colon (b). Symbols are the same as in Fig. 2
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Fig. 4 Receiver-operator characteristic (ROC) curve for chromogranin A cell density for the right (a) and left colon expressed as number of
cells/mm2 epithelium (b)
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found to increase in patients with ulcerative colitis (UC)
and Crohn’s disease (CD) [27]. Furthermore, elevated
plasma and serum chromogranin levels have been reported
in UC and CD patients [28, 29].
The chromogranin A cell density seems to be a good
diagnostic marker with a high sensitivity and specificity.
This was shown to be true whether biopsies were taken
from the right or left colon. Furthermore, chromogranin A
cell density showed the same high specificity and sensi-
tivity when it was measured as number of cells per
microscopic field. This facilitates the use of this marker
even in small laboratories that are not equipped with
computer image analysis facilities. The diagnosis of LC is
based mainly on the finding of intraepithelial lymphocy-
tosis. Lymphocytic infiltration has been reported, however,
to occur more often in the right than in left colon [30]. In
another study, biopsies taken from the left colon (sigmoid
or descending colon) were enough to make the diagnosis in
98.6 % of cases [30]. Thus, the reliability of using flexible
sigmoidoscopy in making the diagnosis LC is not clear, and
remains controversial. Chromogranin A cell density as a
marker showed almost the same high sensitivity and
specificity in biopsies taken from right or left colon,
making sigmoidoscopy suitable for use with this marker.
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